Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From post-surgical cold-compression pumps to neonatal feeding tubes, Avanos Medical’s product line touches some of healthcare’s most sensitive moments. Investors digging into how the company manages regulatory risk, R&D spending, or global recall exposure know the answers live inside its SEC disclosures—yet those files can exceed 300 pages of technical detail.
Stock Titan’s AI engine turns every Avanos Medical quarterly earnings report 10-Q filing and annual report 10-K into plain-language highlights. Need Avanos Medical insider trading Form 4 transactions before the market opens? Our real-time feed surfaces Avanos Medical Form 4 insider transactions real-time and flags patterns in executive stock transactions Form 4. Curious about supply-chain updates or FDA clearances? We tag each Avanos Medical 8-K material events explained so you see the headline without reading footnotes. Even the dense Avanos Medical proxy statement executive compensation is broken down into concise tables.
Here’s how specialists, portfolio managers, and compliance teams use the page:
- Compare non-opioid therapy revenue across periods with Avanos Medical earnings report filing analysis.
- Set alerts for understanding Avanos Medical SEC documents with AI to spot margin-moving disclosures.
- Download red-lined versions of Avanos Medical SEC filings explained simply for faster peer review.
Every document—10-K, 10-Q, 8-K, S-8, Section 16 forms—is captured seconds after EDGAR posts, then summarized by our natural-language model. Historical search lets you trace clinical-trial milestones back through years of Avanos Medical annual report 10-K simplified narratives. Whether you follow digestive-health devices, pain-management trends, or simply want compliance-ready data, Stock Titan delivers the entire picture in one place, saving hours per filing and letting you focus on the investment decision itself.
Avanos Medical filed an amended report to clarify severance terms for two departing executives as part of a broader organizational restructuring. The company eliminated the roles of Chief Commercial Officer and General Counsel, notifying Kerr Holbrook and Mojirade James that their employment would end effective December 1, 2025, with their responsibilities reassigned to other employees.
Under the Severance Pay Plan, Avanos will pay Mr. Holbrook $1,535,417 and Ms. James $1,425,665 in cash severance and cover 100% of their COBRA premiums for 12 months. Time-based restricted stock units for both executives vested pro rata on December 1, 2025, while performance-based awards will vest based on actual performance. The amendment specifies that all 16,300 time-based restricted stock units granted to Ms. James on April 22, 2025 vested in full on that date, and their stock options remain exercisable for up to five years, subject to standard conditions and release agreements.
Avanos Medical, Inc. executive Kerr W. Holbrook, the SVP and Chief Commercial Officer, reported open-market sales of company common stock. On 11/18/2025, he sold a total of 15,000 shares of Avanos Medical common stock in several transactions at prices ranging from $11.00 to $11.02 per share. After these sales, Holbrook directly beneficially owned 83,860 shares of Avanos Medical common stock.
AVNS
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G reporting beneficial ownership of 2,500,000 shares of Avanos Medical, Inc. (AVNS) common stock, representing 5.39% of the class. They report shared voting and shared dispositive power over these shares, with no sole voting or dispositive power. The filing cites 46,418,907 shares outstanding as of October 29, 2025 (per the issuer’s 10‑Q).
The filing is certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control. The date of the event requiring the filing is September 30, 2025.
Avanos Medical (AVNS) reported Q3 2025 results showing modest top-line growth but weaker profitability. Net sales were $177.8 million versus $170.4 million a year ago, driven by Specialty Nutrition Systems (SNS) at $114.0 million and Pain Management & Recovery (PM&R) at $59.0 million. Gross profit fell to $86.0 million from $92.9 million as cost of products sold increased. Operating income was $0.1 million, and the company posted a net loss of $1.4 million (diluted EPS $(0.03)).
Year to date, net sales reached $520.3 million versus $508.2 million, with an operating loss of $64.1 million reflecting a $77.0 million goodwill impairment in PM&R recorded earlier in 2025. Net loss was $71.6 million (diluted EPS $(1.55)). Cash and cash equivalents were $70.5 million, down from $107.7 million at year-end, after funding investments and debt repayments; the revolver was reduced to $0 and the term loan stood at $103.1 million.
Strategic moves included acquiring Nexus Medical for $27.0 million in cash (up to $20.0 million contingent). The deal added $0.9 million of net sales since closing and brought $20.5 million of identifiable intangibles and $14.0 million of goodwill. Restructuring continued, with $10.3 million in Q3 costs; management expects up to $10.0 million additional expenses and annualized savings of $15.0–$20.0 million as initiatives extend through 2026.
Avanos Medical, Inc. filed an 8-K to announce results for the three and nine months ended September 30, 2025. The company reported its results of operations and financial condition for these periods.
The announcement was provided via a press release furnished as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act.
The Vanguard Group filed Amendment No. 12 to Schedule 13G on Avanos Medical (AVNS), reporting beneficial ownership of 3,425,214 shares of common stock, representing 7.38% of the class as of 09/30/2025. Vanguard reports 0 shares with sole voting power and 371,596 with shared voting power. It has 2,979,548 shares with sole dispositive power and 445,666 with shared dispositive power.
Vanguard is identified as an investment adviser and certifies the holdings were acquired and are held in the ordinary course of business and not to change or influence control. Dividends and sale proceeds are for Vanguard’s clients, including registered investment companies and other managed accounts, with no single client over 5%.
Avanos Medical (AVNS) is eliminating its Chief Commercial Officer and General Counsel positions as part of a broader restructuring, effective December 1, 2025. The company notified Senior Vice Presidents Kerr Holbrook (CCO) and Mojirade James (General Counsel and Secretary) of their employment termination tied to the role eliminations, with responsibilities to be reallocated across other employees.
Under the Severance Pay Plan, Avanos will pay $1,535,417 to Mr. Holbrook and $1,425,665 to Ms. James, and cover 100% of COBRA premiums for 12 months. Unvested time-based RSUs will vest pro rata through the termination date, PSUs will vest at period end based on actual performance, and stock options will remain exercisable for five years (or earlier expiration). Each executive will receive a prorated 2025 bonus at target. These benefits are conditioned on signed separation agreements, a general release, and continued compliance with confidentiality and non-solicitation obligations.
Dimensional Fund Advisors LP reports ownership of 2,352,634 shares of Avanos Medical Inc common stock, representing
T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A disclosing beneficial ownership of 4,713,494 shares of Avanos Medical, Inc. common stock, representing
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
